Navigation Links
ISTO Technologies Awarded Key Patent for NuQu™ Injectable Therapy for Degenerative Disc Disease
Date:2/7/2011

ST. LOUIS, Feb. 7, 2011 /PRNewswire/ -- ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office (USPTO) has granted the company a key patent covering the primary technology for ISTO's NuQu™ product.  The new patent, issued on February 1, 2011 as Patent # US-7,879,604, covers the method of cultivating juvenile cartilage cells and injecting those cells into a disc nucleus for the treatment of degenerative disc disease.  

NuQu is an injectable cell-based therapy derived from ISTO's cartilage regeneration platform technology.  It is intended for use as an early intervention treatment for patients suffering from lower back pain.  In preclinical studies, the juvenile chondrocytes used in the NuQu program have shown to be up to 100 times more efficient in producing cartilage matrix than adult cartilage cells.

"The receipt of this patent is an important milestone for the company and is the result of the hard work of many dedicated people over several years.  We believe that our proprietary juvenile chondrocyte-based technology represents a significant potential new treatment option for patients with chronic lower back pain.  Accordingly, an important part of our strategy is to develop a strong intellectual property base to support our product development efforts. We view this recognition by the USPTO of our novel and unique technology as a significant step forward for the NuQu program and for the Company," said Mitchell Seyedin, Ph.D. President & CEO of ISTO.

The company announced the completion of patient enrollment in the Phase I clinical study for NuQu in October 2010.  The study consists of fifteen (15) patients enrolled at two clinical sites. The company anticipates completing data collection of six-month interim results from the trial in early 2011.  All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapies.

In addition to NuQu, the company's other product derived from its cartilage regeneration platform is DeNovo® ET, a scaffold-free engineered cartilage tissue, intended for the repair of damaged articular cartilage in the knee.  DeNovo® ET is developed in partnership with Zimmer, the world's largest provider of reconstructive solutions, and is currently in clinical trials.

In addition to ISTO's cell-based cartilage programs, the company is currently producing and marketing InQu®, a bone graft extender and substitute.  InQu combines integrated hyaluronic acid and a resorbable polymer for better handling and biology. The primary target market for InQu is spinal fusion applications.

About ISTO ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone.  For additional information on ISTO, please visit our website at www.istotech.com. ISTO Technologies, Inc.

Scott Gill

Chief Financial Officer

(314) 995-6049The Ruth Group

Zack Kubow (investors)

(646) 536-7020

zkubow@theruthgroup.comKimberly Muscara (media)

(646) 536-7011

kmuscara@theruthgroup.com
'/>"/>

SOURCE ISTO Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex
2. China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011
3. Long-Term European Data Released for SUPERA® Stent from IDEV Technologies
4. Wound Management Technologies Announces Secure eHealth Technology to be Included During HIMSS 2011 Interoperability Showcase
5. Reportlinker Adds European Markets for Assisted Living Technologies
6. PharmAthene Provides Update on Litigation With SIGA Technologies
7. Advanced Assay Technologies and Development Methods
8. Intrasphere Technologies to Help Develop and Deliver Global Partner Training for the Oracle(R) Argus Safety Suite Through Oracle PartnerNetwork
9. RF Technologies® Announces Distributor Agreement With Universal Hospital Services
10. Nopras Technologies, Inc. Achieves ISO 9001:2008 Certification
11. Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
Breaking Medicine News(10 mins):